急性失代偿性心力衰竭的血液净化治疗

叶嘉炜; 费爱华

doi:10.13201/j.issn.1009-5918.2017.12.021

急性失代偿性心力衰竭的血液净化治疗

叶嘉炜,
费爱华^,

- 上海交通大学医学院附属新华医院(上海, 200092)

详细信息

通讯作者: 费爱华,E-mail:feiaihua@xinhuamed,com.cn

中图分类号: R541.6

收稿日期: 2017-09-24

Blood purification in acute decompensated heart failure

More Information

Corresponding author: , E-mail: feiaihua@xinhuamed,com.cn

Received Date: 24 September 2017

摘要

- 急性失代偿性心力衰竭 /
- 血液净化 /
- 利尿剂 /
- 水钠潴留
Abstract: Acute decompensated heart failure remains a major public health issue.To the patients with ADHF, particularly with severe electrolyte disturbances, renal dysfunction, and hemodynamic instability, first-line drugs recommended by the current guidelines are often ineffective.Blood purification technology not only can effectively improve the retention of water and sodium, but also can remove small molecules such as creatinine, it has become one of the important treatment methods of ADHF.Based on the principle and mode of blood purification technology, this article reviews the indications, therapy timing, advantages and disadvantages of the treatment.
- acute decompensated heart failure /
- blood purification /
- diuretic /
- water-sodium retention

HTML全文

参考文献(24)

[1]	Maze R, Haddad H.An update in the management of acute decompensated heart failure[J].Curr Opin Cardiol, 2014, 29:180-184.
[2]	Mangini S, Pires P V, Braga F G, et al.Decompensated heart failure[J].Einstein (Sao Paulo), 2013, 11:383-391.
[3]	Adams K F, Fonarow G C, Emerman C L, et al.Characteristics and outcomes of patients hospitalized for heart failure in the United States:Rationale, design, and preliminary observations from the first 100, 000cases in the Acute Decompensated Heart Failure National Registry (ADHERE)[J].Am Heart J, 2005, 149:209-216.
[4]	Liu L, Eisen H J, Cardiol C, et al.Epidemiology of heart failure and scope of the problem[J].2014, 32:1-8.
[5]	ACCF/AHA Task Force on Practice Guidelines.Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines.American College of Cardiology and American Heart Association[J].Accessed, 2016.
[6]	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].European JHeart Failure, 2016, 18:891-975.
[7]	Kazory A, Cardiorenal Syndrome:Ultrafiltration Therapy for Heart Failure-Trials and Tribulations[J].Clin J Am Soc Nephrol, 2013, 8:1816-1828.
[8]	Ronco C, Cicoira M, McCullough P A.Cardiorenal syndrome type 1[J].J Am Coll Cardiol, 2012, 60:1031-1042.
[9]	Metra M, Cleland J G, Weatherley B D, et al.Dyspnoea in patients with acute heart failure:An analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study[J].Eur JHeart Fail, 2010, 12:499-507.
[10]	Metra M, Teerlink J R, Felker G M, et al.Dyspnoea and worsening heart failure in patients with acute heart failure:Results from the Pre-RELAX-AHFstudy[J].Eur J Heart Fail, 2010, 12:1130-1139.
[11]	ter Maaten J M, Valente M A, Damman K, et al.Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy[J].Nat Rev Cardiol, 2015, 12:184-192.
[12]	Marenzi G, Muratori M, Cosentino E R, et al.Continuous Ultrafiltration for Congestive Heart Failure:The CUORE[J].Trial J Card Fail, 2014, 20:378-378.
[13]	Rempher K J.Continuous renal replacement therapy for management of overhydration in heart failure[J].AACN Clinical Issues, 2003, 14:512-519.
[14]	Bart B A, Boyle A, Bank A J, et al.Ultrafiltration versus usual care for hospitalized patients with heart failure:the Relief for Acutely Fluid Over-loaded Patients With Decompensated Congestive Heart Failure (RAP-ID-CHF) trial[J].J Am Coll CardioI, 2005, 46:2043-2046.
[15]	Ostanzo M R, Saltzberg M T, Jessup M, et al.Uhrafiltration is associated with fewet rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure:results from UNLOAD[J].JCard Fail, 2010, 16:277-284.
[16]	Bart B A, Goldsmith S R, Lee K L, et al.Ultrafiltration in decompensated heart failure with cardiorenal syndrome[J].N Engl J Med, 2012, 367:2296-2304.
[17]	Costanzo M R, Negoianu D, Fonarow G C, et al.Rationale and design of The Aquapheresis Versus Intravenous Diuretics and Hospitalization for Heart Failure (AVOID-HF) trial[J].Am Heart J, 2015, 170:471-482
[18]	Kelly J P, Mentz R J, Hasselblad V, et al.Worsening heart failure during hospitalization for acute heart failure:Insights from the AcuteStudy of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF)[J].Am Heart J, 2015, 170:298-305.
[19]	Giglioli C, Landi D, Cecchi E, et al.Effects of Ultrafiltration vs Diuretics on clinical, biohumoral and haemodynamic variables in patients with decpmpensated heart failure:the ULTRADISCO study[J].Eur JHeart Fail, 2011, 13:337-346.
[20]	Felker G M, Mentz R J.Diuretics and ultrafiltration in acute decompensated heart failure[J].J Am Coll Cardiol, 2012, 59:2145-2153.
[21]	Cheng Z, Wang L, Hu S, et al.Efficacy and safety of ultrafiltration in decompensated heart failure patients with renal insufficiency[J].Int heart J, 2015, 56:319-323.
[22]	Bart B A, Goldsmith S R, Lee K L, et al.Ultrafiltration in decompensated heart failure with cardiorenal syndrome[J].N Engl J Med, 2012, 367:2296-304.
[23]	Casanova Vivas S.Recommendations from CDC for he prevention of the Catheter-related infections (2013update)[J].Rev Enferm, 2014, 37:28-33.
[24]	Kessler M, Moureau F, Nguyen P, Anticoagulation in chronic hemodialysis:progress toward an optimal approach[J].Semin Dial, 2015, 28:474-489.